Dossier assessment
Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with Waldenström macroglobulinaemia
Added benefit not proven due to lack of suitable study data
Project details
- Project no.
- A19-78
- Commission
- Commission awarded on 02.09.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Ibrutinib (chronic lymphocytic leukaemia) - Addendum to Commission A16-39
Status: Commission completed
-
Dossier assessment
Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ibrutinib - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed